PT-141 is an FDA-approved drug. The approval answers a different question.

Why this note exists

Most compounds in pepmg’s index have no approved drug behind them. This one does, which makes it unusually easy to check a claim against a document — and unusually easy to overstate. In the index generated on August 11, 2026, 91 vendors carried a PT-141 listing, 123 listings in total, putting it eleventh by vendor coverage across the whole registry.[19] Of those listings, 83 are 10 mg vials.[19] The approved product is a single-dose 1.75 mg autoinjector.[1] A vial’s milligram content is not a dose, and pepmg does not convert one into the other.

Because a label exists, pepmg reports what the label says the dose is — 1.75 mg subcutaneously, as needed, no more than one dose in 24 hours, and more than 8 doses per month is not recommended, with discontinuation advised after 8 weeks if symptoms have not improved.[1] That is a published FDA number with a named source, which is safer than leaving people to guess. What this note does not provide is administration technique or any personal recommendation.

A note on what kind of evidence this is: every efficacy and safety figure below comes from randomized trials in humans or from the FDA-approved label that summarizes them. Where a study is in animals — a 2025 Neuropharmacology report of female Syrian hamster analyses — it is named as such, and it speaks to mechanism, not to a human outcome.[13]

Regulatory ledger

What was approved, and what the label rules out

Ledger built from the prescribing information effective November 13, 2025 and the Drugs@FDA record for NDA 210557, queried August 12, 2026, which lists Cosette Pharmaceuticals as sponsor and the product as prescription-only.[1][2]

The second limitation matters as much as the first: the label also states the drug is not indicated to enhance sexual performance.[1] Approval is a decision about a population, an indication and a specific manufactured product. It is not a general endorsement of the molecule.

What the phase 3 trials measured, and how far it moved

The efficacy evidence is RECONNECT: two identical 24-week, randomized, double-blind, placebo-controlled phase 3 trials in premenopausal women with acquired, generalized HSDD of at least six months’ duration. Of 1,267 women randomized, 1,247 were in the safety population and 1,202 in the modified intent-to-treat efficacy population; 85.6% were white, 96.6% were at US sites, and mean age was 39.[3][14][15]

The co-primary endpoints were questionnaire scores, and the label publishes their ranges: the FSFI desire domain runs from 1.2 to 6.0, and FSDS-DAO item 13, which asks how often the patient felt bothered by low sexual desire, runs from 0 to 4.[1]

Mean change from baseline to end of study, modified intent-to-treat population, as tabulated in the FDA-approved label. Integrated across both trials, the published treatment differences were 0.35 for desire (P<.001) and −0.33 for distress (P<.001).[1][3]

The fourth cell is the one that rarely travels, and it is not pepmg’s characterization — it is the label’s. In its own words: “There was no significant difference between treatment groups in the change from baseline to end of study visit in the number of satisfying sexual events (SSEs), a secondary endpoint.”[1] Median change was zero in every arm of both trials.[1] Desire scores and distress scores moved; the count of events did not. Both facts are in the same document, and only one of them is quotable in an ad.

Two more numbers set the scale of use in the trials: the median was 10 injections across the entire 24-week period, and the label states most patients used the drug two to three times per month and no more than once a week.[1] That is the exposure pattern the effect estimate belongs to.

The tolerability numbers are the loudest numbers in the file

Two label findings deserve emphasis in a market with no dose ceiling and no monitoring. First, focal hyperpigmentation: reported in 1% of patients receiving up to 8 doses per month, but in 38% of patients in a study that gave the drug daily for 8 days, with a further 14% developing new pigmentary changes over 8 more consecutive days. The label notes involvement of the face, gingiva and breasts, greater risk with darker skin, and that resolution was not confirmed in all patients after stopping.[1]

Second, blood pressure. The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours post-dose, with heart rate falling by up to 5 beats per minute and values usually returning to baseline within 12 hours. On that basis the drug is contraindicated in uncontrolled hypertension or known cardiovascular disease, is not recommended in patients at high cardiovascular risk, and carries the 24-hour spacing instruction specifically to limit additive blood-pressure effects.[1] The label also records a single case of acute hepatitis during the uncontrolled extension, in a patient who had received 10 doses over a year, with transaminases exceeding 40 times the upper limit of normal that normalized four months after stopping; because no other cause was identified, the label states the drug’s role could not definitively be excluded, while noting no group imbalance in transaminase outliers across the programme.[1]

What the outside literature says about the size of the benefit

An independent systematic review and meta-analysis published in the Journal of Minimally Invasive Gynecology in January 2026 screened 8,994 abstracts and pooled data from 36 studies, 26 of them randomized. It reports that bremelanotide improved total FSFI and its desire and arousal subscales and reduced distress — a real signal, on questionnaires. In the same analysis, mindfulness-based cognitive behavioural therapy improved desire, arousal and orgasm scores, and the authors note that no study directly compared therapy with pharmacotherapy.[6]

A sharper critique exists and should be read as what it is: a single-author re-analysis, published in The Journal of Sex Research in 2021, working from the FDA New Drug Application. It reproduced effects similar to the published ones, but reported that 72.72% of protocol-listed outcomes were not reported in the primary publication while 15 secondary measures that were not in the protocols were; that adverse-event-induced discontinuation was substantially higher on drug (odds ratio 11.98, 95% CI 3.74–38.37); and that on a composite of completing the trial and electing to enter the open-label extension, participants favoured placebo (odds ratio 0.30, 95% CI 0.24–0.38). Its conclusion is that the drug is “generally not useful.”[5] That is one author’s reading, peer-reviewed and accompanied by a published erratum, and it is contested by the approval itself — but the discontinuation asymmetry it highlights is independently visible on the label.[1][5]

The 52-week open-label extension is often quoted for larger numbers, and it cannot bear that weight: it had no control group and its analyses were descriptive only. Of 856 eligible completers, 684 enrolled and 272 finished. Participants previously on bremelanotide changed 1.25 to 1.30 on FSFI-D and −1.4 to −1.7 on FSDS-DAO Q13 from original baseline; participants previously on placebo changed 0.70 to 0.77 and about −0.9.[4] Uncontrolled change over a year is not a treatment effect. A 2026 review of registered HSDD drug trials makes a related point about the field generally: endpoint designation and reporting completeness varied across trials, and safety data were inconsistently reported.[7]

The evidence in men, stated precisely

A registry search on August 12, 2026 returned 10 interventional studies of bremelanotide, and every phase 3 trial enrolled women only.[18][14][15] The two entries open to both sexes are not about sexual function at all: an open-label phase 2b study in diabetic kidney disease with 16 participants, completed in April 2024, and a phase 2 study of bremelanotide co-administered with Tirzepatide for obesity, 108 participants estimated, listed as active and not recruiting. Neither has posted results.[17][16]

Human data in men do exist, and they are old, small, and mostly by a route that never reached approval. A 2004 study administered subcutaneous PT-141 at 0.3 to 10 mg to healthy men and, in a placebo-controlled crossover at 4 and 6 mg, to men reporting an inadequate response to sildenafil, measuring erectile response by RigiScan; responses were statistically significant above 1.0 mg and at both crossover doses.[8] A 2005 crossover study in 19 men combined 7.5 mg intranasal PT-141 with 25 mg sildenafil and reported a greater RigiScan response than sildenafil alone.[9] Both were authored with sponsor involvement, both measured erections inside a laboratory window rather than an outcome over time, and neither is an efficacy trial.

The largest randomized trial in men — 342 men given 10 mg intranasal bremelanotide or placebo, reporting positive clinical results in 33.5% against 8.5% — carries an Expression of Concern published by The Journal of Urology on January 10, 2023.[10][11] pepmg is not in a position to say what is wrong with that paper, and we are not going to guess. The journal has flagged it, and a flagged paper is not a foundation. Meanwhile the question remains open in the literature rather than answered in it: a commentary in the Journal of Clinical Psychopharmacology in mid-2026 asks in its title whether bremelanotide should be considered for sexual arousal and desire disorders in men.[12]

Where the evidence does not reach

Four gaps sit between the approved label and a vial sold as a research chemical.

First, the population. The trials enrolled premenopausal women with a specific diagnosis, 85.6% white and 96.6% at US sites, mean age 39.[3] The label rules out the indication in postmenopausal women and in men.[1]

Second, the outcome. What moved was a two-question desire score and a one-item distress score. The count of satisfying sexual events did not separate from placebo.[1] Any claim about performance is a claim about the endpoint that did not move.

Third, the product and the route. The approved article is a manufactured, single-dose 1.75 mg autoinjector of a specified drug substance.[1] A name match on a storefront establishes no identity, content, impurity profile or sterility, and pepmg does not certify what any vendor ships. The male-focused studies used intranasal delivery at 7.5 to 10 mg — a different route and a different amount from anything approved.[9][10]

Fourth, the conditions of use. The trial effect belongs to a regimen with a monthly cap, a cardiovascular contraindication screened before use, blood pressure checked periodically, and a stop rule at eight weeks.[1] The daily-dosing hyperpigmentation figure — 38% in eight days — is what the label reports when that cap is absent.[1]

Questions people are asking